Edward Dyson

Orrick

Despite equities performing badly throughout the course of 2022, Orrick’s Ed Dyson has managed to thrive in the equity capital markets sector.

This year, Dyson spearheaded Zamaz’s direct listing and also helped to float special purpose acquisition company Codex Acquisitions, as well as mining businesses URA Holdings and Hamak Gold onto the main market of the London Stock Exchange. Dyson has counselled a range of different businesses on dual listings in different jurisdictions, including biotech company OKYO Pharma onto the tech-heavy US Nasdaq and Farmacosmo on listing on the Euronext Growth in Milan.

He worked on a listing step-up for high-growth fintech company VEF and has helped Greek Challenger bank Attica Bank increase its share capital increase gross proceeds of more than €240m.

As the London Stock Exchange still holds untapped potential for 2023, Dyson will continue to flex his ECM muscles, with more listings in his bag for the first quarter of 2023.